2021 AMPLITUDE-O TRIAL M Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes international, randomized, controlled trial Objective: To evaluate efpeglenatide in participants with type 2 diabetes and either a history of cardiovascular disease or current kidney disease 4076 patients Inclusion criteria: Participants ≥18 years of age with type 2 diabetes mellitus and history […]
Tag: type 2 diabetes
ADVANCE Trial Summary: Intensive Glucose Control in Diabetes Type 2
2008 ADVANCE TRIAL Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Multicenter, factorial, randomized trial Objective: To evaluate vascular effects of intensive glycemic therapy targeting a HbA1c <6.5% in patients with type II diabetes 11,140 Patients with DMII diagnosed at ≥30 years of age and hx of major macrovascular or […]
ACCORD Trial: Intensive Glucose Lowering in DM2
ACCORD: Effects of Intensive Glucose Lowering in Type 2 Diabetes Multicenter, double-blinded, two-by-two factorial, randomized controlled trial Objective: To assess if intensive glycemic control targeting a HbA1c <6% versus standard glycemic control targeting a HbA1c 7-7.9% reduce the risk of CV events in patients with type II diabetes. Patients with type II diabetes mellitus 7.9% […]